Pretreatment and postresection epidermal growth factor receptor (EGFR) pathway mutations in a prospective phase II trial (EXCITE) of preoperative cetuximab-containing chemoradiation (CRT) in locally advanced rectal cancer (LARC)

MLA

Lawrie Emma, et al. “Pretreatment and Postresection Epidermal Growth Factor Receptor (EGFR) Pathway Mutations in a Prospective Phase II Trial (EXCITE) of Preoperative Cetuximab-Containing Chemoradiation (CRT) in Locally Advanced Rectal Cancer (LARC).” Journal of Clinical Oncology, vol. 32, Jan. 2014, p. 458. EBSCOhost, https://doi.org/10.1200/jco.2014.32.3_suppl.458.

APA

Lawrie Emma, David Sebag-Montefiore, Shabbir Susnerwala, S. Myint, Sandy Beare, Mark Jitlal, Bruce Sizer, Philip Quirke, Nicholas P. West, Sharadah Essapen, Mark P Saunders, Simon Gollins, & Leslie Samuel. (2014). Pretreatment and postresection epidermal growth factor receptor (EGFR) pathway mutations in a prospective phase II trial (EXCITE) of preoperative cetuximab-containing chemoradiation (CRT) in locally advanced rectal cancer (LARC). Journal of Clinical Oncology, 32, 458. https://doi.org/10.1200/jco.2014.32.3_suppl.458

Chicago

Lawrie Emma, David Sebag-Montefiore, Shabbir Susnerwala, S. Myint, Sandy Beare, Mark Jitlal, Bruce Sizer, et al. 2014. “Pretreatment and Postresection Epidermal Growth Factor Receptor (EGFR) Pathway Mutations in a Prospective Phase II Trial (EXCITE) of Preoperative Cetuximab-Containing Chemoradiation (CRT) in Locally Advanced Rectal Cancer (LARC).” Journal of Clinical Oncology 32 (January): 458. doi:10.1200/jco.2014.32.3_suppl.458.